The Queen Mary BioEnterprises (QMB) Innovation Centre, London’s first completely new build facility for early stage start-up and follow on life sciences and biotechnology companies, has announced the chemistry division of Spirogen, a drug development company developing novel cancer therapies, as their newest tenant.
The QMB Innovation Centre is a wholly owned company of Queen Mary, University of London. The 39,000 square foot facility comprises three floors of high specification work space, including both chemistry and biology laboratory and office suites, for start up science and technology businesses.
The site's flexibility allowed Spirogen suites to be equipped with an air extraction system incorporating eight low electricity consumption chemistry fume hoods, which were installed in a joint design programme with QMB.
Spirogen was founded in 2000 and has one oncology drug, SG2000 currently in Phase II clinical trials and a platform technology for highly potent Antibody-Drug Conjugates (ADC), including partnerships with Genentech, Celtic Therapeutics and ADC Therapeutics.
Ramsay Richmond, Executive manager of QMB commented: “We are very pleased that Spirogen have found with us, modern and affordable commercial chemistry labs inside London. Spirogen had specific discovery chemistry needs, but the Innovation Centre was able to accommodate these in a joint fit-out, illustrating the strength of a modern, easily reconfigurable building. This validates the faith of both funders, QM and the GLA, in supporting an infrastructure intensive building inside London.”
Dr Chris Martin, CEO of Spirogen said: “The state of the art facilities offered by QMB will have a significant impact as we progress our various programmes and technologies. The ability of QMB to provide office space alongside laboratory space, which has been tailored for our specific needs, was a key factor in our decision to come here.”
For more information on QMB Innovation Centre please visit: www.qmbioenterprises.com
For media information, contact: